{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:22:34Z","timestamp":1790716954859,"version":"4.1.0"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Liver cirrhosis is the end stage of various chronic liver diseases (CLDs). The gut microbiota can impact the liver environment and trigger chronic liver inflammation through the gut-liver axis. Alteration of the gut microbiota has become an effective strategy in the biological treatment of cirrhosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty-eight patients with liver cirrhosis and 16 healthy individuals were included, and fresh stool samples were collected. We analyzed changes in the gut microbiota between groups by 16S rRNA sequencing and evaluated the association between microbiota alterations and hepatic function. Additionally, 102 cirrhotic patients were retrospectively enrolled and divided into a probiotic group (n=44) and a nonprobiotic group (n=58) in addition to standard treatment for cirrhosis. Patients were monitored for hematological parameters and hepatic function during the six-month follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The gut microbiota profile of patients with cirrhosis was greatly different from that of healthy individuals, presenting with significantly reduced \u03b1 diversity and decreased abundance of representative SCFA-producing bacteria including\n                      <jats:italic>Firmicutes<\/jats:italic>\n                      ,\n                      <jats:italic>Coprococcus<\/jats:italic>\n                      and\n                      <jats:italic>Clostridium IV<\/jats:italic>\n                      . The pathogenic bacteria\n                      <jats:italic>Gammaproteobacteria<\/jats:italic>\n                      ,\n                      <jats:italic>Veillonella<\/jats:italic>\n                      , and\n                      <jats:italic>Bacilli<\/jats:italic>\n                      were greatly enriched in cirrhotic patients. Additionally, patients with decompensated cirrhosis (DCPC) had a significantly reduced abundance of\n                      <jats:italic>Oscillibacter<\/jats:italic>\n                      compared to compensated cirrhosis (CPC), which is also a SCFA-producing bacteria, and the lower\n                      <jats:italic>Firmicutes<\/jats:italic>\n                      to\n                      <jats:italic>Bacteroidetes<\/jats:italic>\n                      ratio and enhanced MDR values were also shown in DCPC patients compared to CPC patients. In addition, the abundance of\n                      <jats:italic>Firmicutes<\/jats:italic>\n                      was negatively related to hepatic function in cirrhotic patients, including the levels of ALT, AST, and DBIL. From the retrospective study, we found that biochemical improvements in alanine transaminase (ALT) and total bilirubin (TBIL) were obtained in DCPC patients who received oral probiotic therapy compared with the nonprobiotic group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Severe microbial dysbiosis existed in patients with liver cirrhosis, especially patients who reached the decompensatory stage. SCFA-producing bacteria were significantly reduced in cirrhosis. Altered gut microbiota cause changes in functional modules, which may contribute to cirrhosis progression and are associated with clinical prognosis. Adjuvant probiotic supplementation to enhance SCFA-producing bacteria can be a prospective therapy for patients with cirrhosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2023.1218552","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T11:21:49Z","timestamp":1688728909000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Alterations in the gut microbiota and the efficacy of adjuvant probiotic therapy in liver cirrhosis"],"prefix":"10.3389","volume":"13","author":[{"given":"Zengrong","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hejun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deliang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feihong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00018-018-2943-4","article-title":"An insight into gut microbiota and its functionalities","volume":"76","author":"Adak","year":"2019","journal-title":"Cell Mol. Life Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/s0168-1605(01)00550-5","article-title":"Effects of different probiotic strains of lactobacillus and bifidobacterium on bacterial translocation and liver injury in an acute liver injury model","volume":"70","author":"Adawi","year":"2001","journal-title":"Int. J. Food Microbiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/ajg.2012.113","article-title":"Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy","volume":"107","author":"Agrawal","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J. Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1055\/s-0035-1571276","article-title":"Targeting dysbiosis for the treatment of liver disease","volume":"36","author":"Anand","year":"2016","journal-title":"Semin. Liver Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1126\/science.1104816","article-title":"Host-bacterial mutualism in the human intestine","volume":"307","author":"B\u00e4ckhed","year":"2005","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1002\/hep.27819","article-title":"Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy","volume":"62","author":"Bajaj","year":"2015","journal-title":"Hepatology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jhep.2013.12.019","article-title":"Altered profile of human gut microbiome is associated with cirrhosis and its complications","volume":"60","author":"Bajaj","year":"2014","journal-title":"J. Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jhep.2020.01.017","article-title":"Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis","volume":"72","author":"Bajaj","year":"2020","journal-title":"J. Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.3390\/microorganisms10061231","article-title":"Escherichia\/Shigella, SCFAs, and metabolic pathways-the triad that orchestrates intestinal dysbiosis in patients with decompensated alcoholic cirrhosis from Western Mexico","volume":"10","author":"Baltazar-D\u00edaz","year":"2022","journal-title":"Microorganisms"},{"key":"B11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3920\/bm2020.0057","article-title":"Short chain fatty acids in human gut and metabolic health","volume":"11","author":"Blaak","year":"2020","journal-title":"Benef Microbes"},{"key":"B12","doi-asserted-by":"publisher","first-page":"100333","DOI":"10.1016\/j.aohep.2021.100333","article-title":"Deep stool microbiome analysis in cirrhosis reveals an association between short-chain fatty acids and hepatic encephalopathy","volume":"25","author":"Bloom","year":"2021","journal-title":"Ann. Hepatol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2022.159054","article-title":"The antipsychotic drug olanzapine altered lipid metabolism in the common carp (Cyprinus carpio l.): insight from the gut microbiota-SCFAs-liver axis","volume":"856","author":"Chang","year":"2023","journal-title":"Sci. Total Environ."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104403","article-title":"Transplantation of fecal microbiota rich in short chain fatty acids and butyric acid treat cerebral ischemic stroke by regulating gut microbiota","volume":"148","author":"Chen","year":"2019","journal-title":"Pharmacol. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/hep.24423","article-title":"Characterization of fecal microbial communities in patients with liver cirrhosis","volume":"54","author":"Chen","year":"2011","journal-title":"Hepatology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00432","article-title":"Probiotics supplementation therapy for pathological neonatal jaundice: a systematic review and meta-analysis","volume":"8","author":"Chen","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.598152","article-title":"Gut microbiome of children and adolescents with primary sclerosing cholangitis in association with ulcerative colitis","volume":"11","author":"Cortez","year":"2020","journal-title":"Front. Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/hep.24341","article-title":"Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells","volume":"54","author":"Csak","year":"2011","journal-title":"Hepatology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1053\/j.gastro.2014.08.031","article-title":"Probiotic VSL3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial","volume":"147","author":"Dhiman","year":"2014","journal-title":"Gastroenterology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/14728214.2021.1918099","article-title":"Emerging synthetic drugs for the treatment of liver cirrhosis","volume":"26","author":"Fallowfield","year":"2021","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.1124234","article-title":"Metagenomic analysis of the human distal gut microbiome","volume":"312","author":"Gill","year":"2006","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/s0140-6736(21)01374-x","article-title":"Liver cirrhosis","volume":"398","author":"Gin\u00e8s","year":"2021","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s10482-020-01474-7","article-title":"Human gut microbiota\/microbiome in health and diseases: a review","volume":"113","author":"Gomaa","year":"2020","journal-title":"Antonie Van Leeuwenhoek"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.clnu.2017.04.021","article-title":"Effects of continuous use of probiotics before liver transplantation: a randomized, double-blind, placebo-controlled trial","volume":"36","author":"Gr\u0105t","year":"2017","journal-title":"Clin. Nutr."},{"key":"B25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.canlet.2021.11.027","article-title":"Gut microbiota-derived short-chain fatty acids and colorectal cancer: ready for clinical translation","volume":"526","author":"Hou","year":"2022","journal-title":"Cancer Lett."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101706","article-title":"Short-chain fatty acid metabolism and multiple effects on cardiovascular diseases","volume":"81","author":"Hu","year":"2022","journal-title":"Ageing Res. Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1161\/circresaha.122.320771","article-title":"Gut dysbiosis promotes preeclampsia by regulating macrophages and trophoblasts","volume":"131","author":"Jin","year":"2022","journal-title":"Circ. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1111\/liv.14106","article-title":"Faecal microbiota from patients with cirrhosis has a low capacity to ferment non-digestible carbohydrates into short-chain fatty acids","volume":"39","author":"Jin","year":"2019","journal-title":"Liver Int."},{"key":"B29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/apt.16200","article-title":"Microbiome as a potential diagnostic and predictive biomarker in severe alcoholic hepatitis","volume":"53","author":"Kim","year":"2021","journal-title":"Aliment Pharmacol. Ther."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2020.1785251","article-title":"Changes in the fecal bacterial microbiota associated with disease severity in alcoholic hepatitis patients","volume":"12","author":"Lang","year":"2020","journal-title":"Gut Microbes"},{"key":"B31","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1161\/circresaha.119.316448","article-title":"Gut microbiota-derived short-chain fatty acids promote poststroke recovery in aged mice","volume":"127","author":"Lee","year":"2020","journal-title":"Circ. Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3390\/ijms22010199","article-title":"The role of the gut microbiome in liver cirrhosis treatment","volume":"22","author":"Lee","year":"2020","journal-title":"Int. J .Mol. Sci."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100448","article-title":"Restoration of the gut microbiota is associated with a decreased risk of hepatic encephalopathy after TIPS","volume":"4","author":"Li","year":"2022","journal-title":"JHEP Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1039\/c7fo00355b","article-title":"The hepatoprotective effect of the probiotic clostridium butyricum against carbon tetrachloride-induced acute liver damage in mice","volume":"8","author":"Liu","year":"2017","journal-title":"Food Funct."},{"key":"B35","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1021\/jf5039184","article-title":"Protective effects of selenium-enriched probiotics on carbon tetrachloride-induced liver fibrosis in rats","volume":"63","author":"Liu","year":"2015","journal-title":"J. Agric. Food Chem."},{"key":"B36","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41588-021-00968-y","article-title":"Mendelian randomization analyses support causal relationships between blood metabolites and the gut microbiome","volume":"54","author":"Liu","year":"2022","journal-title":"Nat. Genet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1093\/nutrit\/nuy031","article-title":"Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"76","author":"Loman","year":"2018","journal-title":"Nutr. Rev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/hep.31523","article-title":"The commensal microbe veillonella as a marker for response to an FGF19 analog in NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.cgh.2013.11.006","article-title":"Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial","volume":"12","author":"Lunia","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1111\/1462-2920.13401","article-title":"Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis","volume":"18","author":"Lv","year":"2016","journal-title":"Environ. Microbiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1241894","DOI":"10.1155\/2020\/1241894","article-title":"Melatonin alleviates neuroinflammation and metabolic disorder in DSS-induced depression rats","volume":"2020","author":"Lv","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"key":"B42","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1017\/s0007114514004206","article-title":"Dietary trans-10, cis-12-conjugated linoleic acid alters fatty acid metabolism and microbiota composition in mice","volume":"113","author":"Marques","year":"2015","journal-title":"Br. J. Nutr."},{"key":"B43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1017\/s0029665120006916","article-title":"SCFA: mechanisms and functional importance in the gut","volume":"80","author":"Martin-Gallausiaux","year":"2021","journal-title":"Proc. Nutr. Soc."},{"key":"B44","doi-asserted-by":"publisher","first-page":"557","DOI":"10.4254\/wjh.v13.i5.557","article-title":"Gut dysbiosis is associated with poorer long-term prognosis in cirrhosis","volume":"13","author":"Maslennikov","year":"2021","journal-title":"World J. Hepatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1016\/j.cgh.2019.07.060","article-title":"Contemporary epidemiology of chronic liver disease and cirrhosis","volume":"18","author":"Moon","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/19490976.2015.1134082","article-title":"Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism","volume":"7","author":"Morrison","year":"2016","journal-title":"Gut Microbes"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1017\/s0950268820003143","article-title":"Serum lactate level predicts 6-months mortality in patients with hepatitis b virus-related decompensated cirrhosis: a retrospective study","volume":"149","author":"Nie","year":"2021","journal-title":"Epidemiol. Infect."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00277","article-title":"Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases","volume":"10","author":"Parada Venegas","year":"2019","journal-title":"Front. Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.nut.2010.01.006","article-title":"Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study","volume":"27","author":"Pereg","year":"2011","journal-title":"Nutrition"},{"key":"B50","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.cgh.2016.10.029","article-title":"Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study","volume":"15","author":"Philips","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1111\/jgh.15899","article-title":"The effect of increasing intestinal short-chain fatty acid concentration on gut permeability and liver injury in the context of liver disease: a systematic review","volume":"37","author":"Pohl","year":"2022","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nature13568","article-title":"Alterations of the human gut microbiome in liver cirrhosis","volume":"513","author":"Qin","year":"2014","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106348","article-title":"Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury","volume":"182","author":"Rodriguez-Diaz","year":"2022","journal-title":"Pharmacol. Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"350","DOI":"10.52547\/ibj.3772","article-title":"Dynamic population of gut microbiota as an indicator of inflammatory bowel disease","volume":"26","author":"Salimi","year":"2022","journal-title":"Iran BioMed. J."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/s41591-019-0485-4","article-title":"Meta-omics analysis of elite athletes identifies a performance-enhancing microbe that functions via lactate metabolism","volume":"25","author":"Scheiman","year":"2019","journal-title":"Nat. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1113\/jphysiol.2011.219691","article-title":"Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut","volume":"590","author":"Seki","year":"2012","journal-title":"J. Physiol."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.03166","article-title":"Disorganized gut microbiome contributed to liver cirrhosis progression: a meta-Omics-Based study","volume":"9","author":"Shao","year":"2018","journal-title":"Front. Microbiol."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2022.100676","article-title":"Gut microbiota dysbiosis in patients with hepatitis b virus-related cirrhosis","volume":"27","author":"Shu","year":"2022","journal-title":"Ann. Hepatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1053\/j.gastro.2020.08.054","article-title":"Alterations in gut microbiome in cirrhosis as assessed by quantitative metagenomics: relationship with acute-on-Chronic liver failure and prognosis","volume":"160","author":"Sol\u00e9","year":"2021","journal-title":"Gastroenterology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.3390\/microorganisms8111715","article-title":"The influence of probiotics on the Firmicutes\/Bacteroidetes ratio in the treatment of obesity and inflammatory bowel disease","volume":"8","author":"Stojanov","year":"2020","journal-title":"Microorganisms"},{"key":"B61","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jcmgh.2019.04.008","article-title":"Predicting clinical outcomes of cirrhosis patients with hepatic encephalopathy from the fecal microbiome","volume":"8","author":"Sung","year":"2019","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.1097\/meg.0000000000001978","article-title":"The diagnostic potential of gut microbiome for early hepatitis b virus-related hepatocellular carcinoma","volume":"33","author":"Tang","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","article-title":"The gut-liver axis and the intersection with the microbiome","volume":"15","author":"Tripathi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1053\/jhep.2001.25350","article-title":"Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice","volume":"34","author":"Uesugi","year":"2001","journal-title":"Hepatology"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106062","article-title":"Inulin alleviates inflammation of alcoholic liver disease via SCFAs-inducing suppression of M1 and facilitation of M2 macrophages in mice","volume":"78","author":"Wang","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/gutjnl-2018-317836","article-title":"Alterations of gut microbiome in autoimmune hepatitis","volume":"69","author":"Wei","year":"2020","journal-title":"Gut"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/s41598-017-01387-y","article-title":"Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-n-oxide in chronic kidney disease patients","volume":"7","author":"Xu","year":"2017","journal-title":"Sci. Rep."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.739337","article-title":"Effectiveness of probiotics and prebiotics against acute liver injury: a meta-analysis","volume":"8","author":"Xu","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"B69","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.nutres.2022.07.007","article-title":"Therapeutic potential of short-chain fatty acid production by gut microbiota in neurodegenerative disorders","volume":"106","author":"Yadav","year":"2022","journal-title":"Nutr. Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00535-021-01788-x","article-title":"Evidence-based clinical practice guidelines for liver cirrhosis 2020","volume":"56","author":"Yoshiji","year":"2021","journal-title":"J. Gastroenterol."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.12659\/msm.924040","article-title":"Protective effect of probiotics against esophagogastric variceal rebleeding in patients with liver cirrhosis after endoscopic therapy","volume":"26","author":"Zhang","year":"2020","journal-title":"Med. Sci. Monit."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.914684","article-title":"Effect and mechanism of bifidobacterium animalis B94 in the prevention and treatment of liver injury in rats","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.hbpd.2019.01.002","article-title":"Relationship between intestinal microbial dysbiosis and primary liver cancer","volume":"18","author":"Zhang","year":"2019","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"B74","doi-asserted-by":"publisher","first-page":"6701","DOI":"10.1038\/s41598-023-33806-8","article-title":"Gut microbiota induces hepatic steatosis by modulating the T cells balance in high fructose diet mice","volume":"13","author":"Zhou","year":"2023","journal-title":"Sci. Rep."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1218552\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T11:21:52Z","timestamp":1688728912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1218552\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":74,"alternative-id":["10.3389\/fcimb.2023.1218552"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1218552","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]},"article-number":"1218552"}}